Objectives: Numerous factors influencing medication adherence in chronically ill patients are well documented, but the paucity of studies concerning initial treatment course experiences represents a significant knowledge gap. As interventions targeting this crucial first phase can affect long-term adherence and outcomes, an international panel conducted a systematic literature review targeting behavioral or psychosocial risk factors. Methods: Eligible published articles presenting primary data from 1966 to 2011 were abstracted by independent reviewers through a validated quality instrument, documenting terminology, methodological approaches, and factors associated with initial adherence problems. Results: We identified 865 potentially relevant publications; on full review, 24 met eligibility criteria. The mean Nichol quality score was 47.2 (range 19-74), with excellent reviewer concordance (0.966, P o 0.01). The most prevalent pharmacotherapy terminology was initial, primary, or first-fill adherence. Articles described the following factors commonly associated with initial nonadherence: patient characteristics (n ¼ 16), medication class (n ¼ 12), physical comorbidities (n ¼ 12), pharmacy co-payments or medication costs (n ¼ 12), health beliefs and provider communication (n ¼ 5), and other issues. Few studies reported health system factors, such as pharmacy information, prescribing provider licensure, or nonpatient dynamics. Conclusions: Several methodological challenges synthesizing the findings were observed. Despite implications for continued medication adherence and clinical outcomes, relatively few articles directly examined issues associated with initial adherence. Notwithstanding this lack of information, many observed factors associated with nonadherence are amenable to potential interventions, establishing a solid foundation for appropriate ongoing behaviors. Besides clarifying definitions and methodology, future research should continue investigating initial prescriptions, treatment barriers, and organizational efforts to promote better long-term adherence.
Introduction
Medication adherence is defined as "the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regime" [1] . There are two types of medication adherence: initial adherence, where the patient fills the medication the first time it is prescribed, and continued adherence, where the patient continues to refill the medication. Numerous factors pertaining to poor medication adherence in general for chronically ill patients are well documented. Although a comprehensive list of potential influences would include hundreds of barriers, McHorney [2] summarized the proximal drivers of self-reported adherence problems: 1) perceived drug harms versus benefits, 2) the need for their medication, and 3) out-of-pocket pharmacy costs. There exists, however, a paucity of studies concerning experiences during the very beginning of the treatment course (often referred to as either "primary, initial, or first-fill adherence"), representing a crucial knowledge gap in understanding why patients choose to begin taking medication. Accurately determining the rate of initial adherence is a challenge, because there is currently no validated, systematic means of determining this process through existing records. Nevertheless, it was estimated that in a national study comprising the vast majority of retail pharmacy prescriptions in the United States, the prevalence of new-fill abandonment was 6.3% in 2009, up from 5.1% the prior year [3] .
A challenge with evaluating initial adherence stems from an inability to connect the actions that occur in the prescriber's office with the patient's actions outside the office. Although this disconnect may decrease with the rise of new technologies such as electronic systems linking medication prescribers with dispensers more efficiently, at present there are few studies that have attempted to measure initial adherence let alone rigorously define it or summarize factors that influence this issue. In a survey of more than 9000 patients, the Boston Consulting Group reported that 18% of the patients did not fill a prescription in the past 12 months, with 10% giving as a primary reason for nonadherence that they "can't get prescription filled, picked up or delivered" [4] . Other small, nongeneralizable studies about the rate of initial adherence do exist, but these are insufficient to establish a true estimate of the rate of initial nonadherence. These studies have studied either only specific conditions such as asthma [5] or specific settings such as pharmacies [6] . Further complicating the picture are the various definitions used to describe initial medication behavior. Initial nonadherence can be when a patient fails to present a prescription to the pharmacy after it has been first ordered by the health care provider, or neglects to claim a prescription after it has been filled by the pharmacist.
Initiating a medication regimen (i.e., initial adherence) may be the beginning of a complex series of behavior changes that can have a long-term effect on a patient's health and well-being. Therefore, understanding factors that influence this initial behavior can enable the clinician and the health system to identify targeted interventions at this crucial stage in the treatment process to improve the patient's adherence behaviors and longer term outcomes. To that end, the Medication Adherence and Persistence working group of the International Society of Pharmacoeconomics and Outcomes Research undertook this systematic review of the literature to identify the current state of research in this area. The aims of this analysis were to summarize the current body of literature focused on how researchers are currently using terminology for initial medication adherence (and internal consistency within their studies), identify the research strengths and gaps, document potential behavioral or psychosocial risk factors associated with poor adherence during this early treatment phase, and offer recommendations for further research in this area.
Methods
An international panel of researchers with considerable expertise in medication adherence began the process of selecting relevant articles by conducting a comprehensive, systematic review of the published literature, and then documented risk factors related to initial nonadherence. This literature search spanned multiple databases covering the period from 1966 through July 2012 and included Medline (PubMed, Ovid), the Cochrane Library, PsycInfo, Scopus, Web of Science, Embase, and CINAHL. The following standardized search terms were used, all in conjunction with and without the term medication, along with "treatment," "pharmacy," and "prescriptions": primary, initial (non)adherence, primary, initial (non)compliance, and first fill adherence/compliance, In addition to the general term of "risk factor," these key terms were cross-referenced with a lengthy list of potential factors documented to be associated with poor adherence, or conversely, better adherence. These included items such as patient characteristics, medication beliefs, cost, and number of health conditions or comorbidities. Given the multitude of possible key terms and related concepts, please refer to the Appendix in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2013.04.014 for additional details concerning our search terms and overall strategy. We also iteratively searched the bibliographies of included articles as well as relevant review articles for additional eligible publications; this follow-up effort yielded approximately 20 potentially new articles, but none that met final inclusion criteria.
Limiting the selection to English publications, we required that the studies conducted work on primary data analysis, with additional exclusions made for case series with fewer than 10 patients, or articles presenting conceptual or theoretical work. To restrict our focus on a limited definition of initial adherence as defined by the study authors, further discussions and a complete review of articles led to excluding those dealing with adherence during the early treatment course or longitudinal persistence, rather than factors associated with the very first prescription. These criteria were applied during the review of the article titles, key words, our initial review of abstracts, and during the thorough full-text review.
Articles meeting final eligibility requirements were then assessed by two independent reviewers through a validated quality instrument documenting methodological details; the Nichol tool evaluates multiple dimensions of research quality, including study design, how disease conditions were defined, and descriptions of adherence measurement [7] . Scaled scores are assigned to a range from 0 to 100, and we report the mean and variance for all included articles. Each article was then fully extracted by at least two independent reviewers to document information concerning adherence definitions (e.g., primary, initial, and other), study type (randomized controlled trial, observational, prospective), the pharmacy data collection method (ordered prescriptions vs. filled claims, or patient self-report), methodology concerning adherence measurement (e.g., number of fills within 90 days, medication possession ratio [MPR] , and other techniques), acute and/or chronic disease state and specific diagnoses, and therapeutic drug class. Additional information was collected on patient demographics (including race/culture, socioeconomic status [SES], health literacy), practitioner type (primary care, specialist, nurse practitioner, etc.), prescribing system (electronic, paper), location of dispensing pharmacy (HMO, chain, community), and patient insurance type and/or pharmacy co-payments. Finally, as the primary outcome of interest for this review, significant factors affecting initial adherence were summarized, based on the statistically significant results as reported by the study authors, along with observations concerning study limitations.
After the comprehensive data extractions were completed and new searches revealed no further included articles, the study team again reviewed and summarized these data to confirm a final inclusion list, discuss terminology and central themes, and resolve potential conflicts between reviewers. We also present the most prevalent factors examined in these studies and the reported association with nonadherence, and summarize relative effect sizes determined by the authors. Because relatively few articles also examined the association between initial adherence and other clinical outcomes, these are noted as a secondary aim with further discussion of this implication of medication behavior.
Results

Search Results
Overall, the search identified 865 potentially relevant articles, of which 307 abstracts were deemed eligible for review of additional details. The most common exclusion reason by far was an obvious lack of focus on initial adherence (n ¼ 198), despite implying such an objective in the publication title or key words. Other exclusions included articles not analyzing unique primary data [8] , smaller case series [9] , conceptual or theoretical articles [10] , and non-English articles [3] . Therefore, only 63 articles were V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 9 1 -9 0 0 most likely relevant and therefore thoroughly evaluated in full to determine final inclusion. Of these, articles were then further eliminated where the authors used terminology for initial adherence broadly documenting treatment adherence, longitudinal persistence, or discontinuation ranging from 1 month to 2 years after the first prescription. This task required a comprehensive review of study methodology and team member consensus to confirm a focus on initial adherence. Thus, only 24 articles made our final inclusion list. With the study design flowchart depicted in Figure 1 , these selected publications were then fully extracted and evaluated per the aforementioned description. Table 1 presents a summary of the final included articles. In terms of the assessed quality, the mean Nichol score for these articles was 47.2 Ϯ 14.2, with a range between 18.5 and 74.1. Both reviewers closely agreed in their evaluations with an interclass correlation coefficient for the total score of 0.966 (95% confidence interval 0.948-0.974; P o 0.01).
None of the 24 studies was a randomized trial, and few presented findings from prospective study designs; two were conducted from the prescriber offices and prescription data [10, 11] , and four used prospective data collection by patient survey [9, 20, 30, 31] . Most articles, however, relied on observational or retrospective examinations of secondary pharmacy data sets. Two studies supplemented their analyses with either telephone interviews [12] or a large number of survey responses [16] to query patient reasons concerning initial nonadherence. Although a third of the analyses examined medications for acute conditions, most covered chronic health conditions over a wide range of physical and psychiatric disorders or drug classes, including hypertension, diabetes, cardiovascular disease, depression or anxiety, asthma, osteoporosis, epilepsy, cancer, and multiple sclerosis. Few articles provided details concerning the specific prescriber (physician, nurse practitioner, other), information about the pharmacy system (e.g., electronic scripts, mailed fills), or whether the dispensing pharmacy was part of the health system or a community pharmacy. No studies described organizational or other nonpatient factors associated with initial adherence.
Study Populations
Cohort size varied greatly across the studies, ranging from 60 patients [10] to extremely large populations of 5.2 million [25] , covering a few hundred to over 10 million total prescriptions [25, 27] . In terms of demographic characteristics (weighted by individual study sample size), the majority of participants in these studies were female (average 55%, range 32%-62%), while the mean patient age in the 16 articles providing data was 56.2 years (range 15-81þ). Fourteen studies were conducted on predominantly Caucasian populations including three Scandinavian studies, although the primary language spoken was not clarified. Eight publications did not report racial/ethnic demographics, and participants' SES was not reported in 13 studies. However, six studies were conducted on individuals with relatively higher incomes (e.g., 4US $50,000 annually). Five studies included predominantly lower socioeconomic groups, whereas three studies reported smaller proportions in this social stratum. The specific type of health insurance was not stated in seven articles. When documented, health insurance benefits primarily consisted of pharmacy co-payment systems decreasing with total expenditures. Two studies included fully insured participants, while others described combinations of insurance systems specific to that country. Health literacy was not directly examined in any of the articles, though six studies reported limited evidence of educational levels; one article reported 25% participants with some college [14] , though the others noted approximately 20% without a high school diploma.
Medication Adherence: Frequently Used Terminology and Methodology
With considerable overlap of definitions, the most prevalent adherence terminology was primary, used in 46% (11 of 24) of the eligible publications. Initial was the second most commonly used term, observed in 42% [20] of the eligible publications, followed by first-fill adherence in 38% [10] of the final articles. The term "early adherence" was seen only once in the included publications, used in addition with another definition, along with a variety of other infrequent terms including new or first prescription, treatment initiation, and index fill. Conducting an updated search on these additional terms did not reveal further articles. Three studies examining prescription abandonment, defined as a patient not picking up a prescription presented at the pharmacy, were included in the final list because these articles also used another initial adherence term and appeared to frame their studies in that context [14, 25, 28] . From the 63 original articles thoroughly reviewed, 39 were excluded because it was clear that they did not examine the very first prescription. Instead, these articles presented adherence over a period covering the early treatment course, ranging from a month to 2 years following the index prescription. Thus, although the key words and abstracts asserted that these studies targeted initial adherence, the methodology indicated that they were not appropriate for our working definition.
Adherence Measurement
In contrast to our objective of focusing on initial adherence, it became clear that despite using the aforementioned terms to denote initial adherence and noting this fact in "Methods" sections, authors frequently meant that initial adherence was the length of time from the first prescription until it was filled, although this period varied and alternatives approaches were observed. The most prevalent time frame was having a further exclusions
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Fig. 1 -Study design and systematic review flow chart. [8, [21] [22] [23] 25, 27, 29] , although 2 to 3 months was also common [9] [10] [11] 14, 16, 28] ; longer periods were also used several times, including 4 to 7 months [12, 15] , and even up to a year [13, 31] . Survival analyses were conducted twice to examine time until a fill ranging from the first 2 months [17] to 5 years [26] ; the first study used a multivariable discrete-time period approach, while the latter used both Kaplan-Meier and Com proportional hazard models. Notwithstanding, however, the terminology for initial adherence, suggesting a distinct first prescription, a broader perspective or use of multiple outcomes was occasionally noted, further complicating our analysis. For example, the MPR greater than 80% over a 1-year period defined adherence persistence for Ko et al. [18] , yet the authors also examined a 14-day prescription delay following the receipt of a coronary stent. Similarly, Kretzer et al. [19] used a combination of MPR, gaps, or switches from an initial drug during 1 year. In other studies, reasons for both initiating and discontinuing medications during a 6-month period were examined [20] , as was the proportion of days covered (PDC, comparable to MPR) for patients initiating treatment along with prescription switches [24] . Finally, Wamala et al. [30] documented self-reported prescription failure within 90 days, yet it was unclear whether these were restricted to initial treatment or any fills.
Prevalence of Poor Adherence
Based on each study definition, we summarized reported rates of initial nonadherence. Of the 20 articles with the clearest definitions (i.e., single outcome, no initial prescription within a finite number of months), these rates varied between 2.3% and 50%.
Recognizing the large sample size differences between 60 and over 5 million, the weighted average was 5.1% Ϯ 1.3%. When studies reported the total number of prescriptions (n ¼ 6), poor adherence ranged between 2% and 50%. A more complex summary of outcomes was observed in four articles with longer observational windows or those looking at multiple drug classes. For example, Ko et al. [18] found prescription noninitiation rates of 16% and 7% (1 week and 1 year, respectively) following receipt of coronary stents; longer term persistence of 16% to 26% at 3 to 6 months was calculated by using the MPR. Kretzer et al. [19] found that longer term poor adherence ranged between 45% and 80% depending on drug class, as did Shrank et al. [24] using the PDC over a year, finding rates of 21% to 65% across specific medication classes. Wamala et al. [30] , not distinguishing between initial versus any fill, found poor adherence rates between 4% and 11% by drug class.
Factors Associated with Poor Initial Adherence
Turning to the primary outcome of interest, numerous issues associated with initial adherence were identified. Table 2 presents a quantitative summary of only the statistically significant findings from across the 24 studies, along with a summary of the reported strength of association in relation to initial adherence (i.e., odds ratios [ORs]). The most prevalent factor addressed was observed differences by drug class or specific medication (n ¼ 16). While actual rates are difficult to compare because of the diversity and the sheer number of drugs analyzed, patients consistently failed to fill prescriptions for several medication types. Most notably, this included prescriptions for dermatological conditions [11, 13] and calcium channel blockers [17, 23, 24] , along with urinary tract or obstetrics medications and oral contraceptives [11, 12, 24] . Poor adherence rates were also high in treatment for infections [11] , injectable anticoagulants [15] , loop diuretics [23] , antipsychotics [25] , and nutritional supplements or cold and allergy medications [15, 25] . Conversely, better adherence rates were observed for angiotensin-converting enzyme inhibitors [15, 23, 24] , statins [15, 24] , antibiotics [12, 25] , beta blockers [19, 23] , and opiates [25] . Beardon et al. [11] and Ekedahl and Mansson [12] documented similar findings concerning drugs with higher (cardiovascular, generally defined) and lower adherence rates (respiratory, musculoskeletal). Other psychotropic drugs had mixed findings, with better adherence for antianxiety medications [13] ; antidepressants had better reported rates in one study [25] while among the lowest in another article [15] . In addition to the effect on initial adherence, Karter et al. [16] also compared three drug classes over a longer time period (i.e., outcomes of none or only one fill during a 2-year window), finding that high cholesterol prescriptions were filled at half the rate of antihypertensive and hyperglycemic drugs. Also examining two outcomes, any initial fill within 30 days and the 180-day PDC, Raebel et al. [8, 21] noted that diabetes and hyperlipidemia scripts failed twice as often as hypertensive medications. Shah et al. [22] . found that oral hypoglycemic medications, biguanide and sulfonylurea (11% and 14%, respectively), were filled far more often than insulin (26%) [22] . Examining eight different oral oncolytics, Streeter et al. [28] documented poor adherence rates ranging from 6.2% (capecitabine) to 27.2% (sorafenib). One article focused on a single drug class, and so no medication comparison was conducted [29] . While Gleason et al. [14] focused on the role of co-payments, they briefly explored drug class interactions with cost, finding less price sensitivity for multiple sclerosis agents than for tumor necrosis factor blockers. Storm et al. [27] directed their analysis to selected health conditions rather than drug class, though they noticed that diagnoses associated with lowest initial adherence (e.g., psoriasis and eczema) tended to have topical drug applications. A total of 14 articles presented associations between demographics or other patient characteristics and initial adherence, notably age; although younger patients were often substantially less adherent [12, 24, 25, 27, 28, 31] , several articles observed that middle aged or older patients experienced more difficulty with initial prescriptions [11, 13, 15, 23, 29, 30] . Not only low SES was frequently an adherence barrier, primarily income, but also individuals living alone or with poor social support [8, 15, 18, 24, 25, 28, 30] , although Wroth and Pathman [31] observed that married patients were 30% more likely to have adherence problems. Overall, men exhibited significantly better adherence in most articles specifically reporting on gender [13, 24, 25, 31 ], yet worse behavior in another study [12] . Race/ethnicity was less commonly examined, though minorities generally were less adherent [8, 31] ; van Geffen et al. [29] also noted that nonWestern immigrants failed to initiate antidepressant treatment at higher rates. Patients in rural areas were slightly less likely to fill first prescriptions in one study examining geographic residency [25] .
Broadly considered, illness severity and disease chronicity were also examined in 14 articles. Factors negatively influencing adherence included patients with a greater number of physical illnesses [25] , a higher Charlson comorbidity score [23] , experiencing a recent acute myocardial infarction or heart failure [18] , frequent health system contacts prior to the initial fill [8] , and having currently elevated hemoglobin A 1c or blood pressure levels [22] . In addition, patients having chronic conditions such as diabetes [13] or, for example, psoriasis rather than an acute skin infection [27] , individuals lacking current serious symptoms such as asthma exacerbations or severe coughing [20] , and patients self-reporting either long-term illnesses or fair to poor overall health status [30, 31] tend to display worse initial adherence behavior. Kessler et al. [17] explored the interaction between pharmacy co-payments and 10 different diagnoses, observing that asthma and rhinitis prescriptions were most sensitive to medication cost while diabetes, epilepsy, and hypertension drugs H 1 6 ( 2 0 1 3 ) 8 9 1 -9 0 0 were least affected. Similarly, while concentrating on pharmacy naive patients and medication costs, Solomon et al. [26] found that higher co-payments led to sharper declines in refills for hypertension and high cholesterol drugs (27% and 29%, respectively) than for diabetes medications (11% drop). Examining perhaps another proxy for illness burden, the number of medications taken by a patient was positively related to lower adherence, such as a greater quantity prior to a myocardial infarction as described by Jackevicius et al. [15] , or for oral oncology adherence in general [28] . Raebel et al. [8] , however, found that patients receiving fills in multiple drug classes actually experienced better adherence initially.
Pharmacy co-payments or out-of-pocket medication expenses, reported in 11 articles, represented perhaps the strongest association with poor initial adherence in terms of effect size or ORs (see below and Table 2 ). Although two studies observed no or minimal adherence differences by co-payment status [8, 16] , others documented a significant influence of medication cost on initial fill behavior [12] . Gleason et al. [14] reported a strong linear effect across co-payment levels, ranging from a 5% failed initiation rate for patients paying less than $100 to over 25% as cost exceeded $500 for expensive specialty drugs. For oncology medications, a comparable co-payment range led to a fourfold adherence difference [28] . Summarizing a detailed analysis by Kessler et al. [17] , the co-payment level was significantly associated with treatment termination, ranging from 1% to 40% as out-of-pocket costs increased. First-fill adherence problems were consistently seen in other studies, rates nearly doubling when patients faced even $10 co-payments [11, 22, 23] . The risks were substantially greater in prescriptions attached to $40 to $50 (ORs of 3.5-4.5 vs. fills with no co-payments) [16] . Two additional studies [24, 26] did not directly examine co-payments, instead analyzing the effects of multitiered pharmacy benefits as a proxy for medication costs, with similar findings that patients used fewer nonpreferred drugs.
Medication beliefs and provider relationships frequently influenced initial adherence behavior. Yood et al. [9] observed that initial adherence rates for osteoporoses nearly doubled in patients believing that the medication was effective, along with understanding that their condition warranted treatment, a finding echoed by another study [12] . In a randomized trial, Raue et al. [10] determined that patients offered treatment strongly congruent with their preferences and effectiveness beliefs (whether medication, therapy, or no care) had much better prescription initiation and 4-month adherence rates. A low sense of trust in the health care system overall was associated with 3.5 times the likelihood of poor adherence, with older patients experiencing worse problems [30] . Wroth and Pathman [31] also found that poor adherence was strongly associated with dimensions of trust and the therapeutic alliance, including lacking confidence in their doctor's ability to help them, and low satisfaction with their quality of care. In addition, Shrank et al. [25] point out that patients often avoided nonpreferred medications, another expression of treatment preferences. Also described to some extent in five studies, certain physician characteristics were correlated with lower initial adherence, such as scripts written by a trainee, junior, or younger physician [11, 13, 27] . Prescriptions written by inpatient cardiology specialists were filled more frequently [15] , yet outpatient scripts originating from primary care physicians were filled more often than scripts for patients seeing specialist providers [8] .
A variety of other factors were found to be associated with initial adherence. Poor treatment response, reflecting either past patient experience or new prescriptions, was negatively associated with initial adherence [16, 20] ; not surprisingly, medication side effects also reduced the likelihood of adherence, though directly examined in only one study [20] . A variety of other factors associated with initial adherence included electronic prescriptions less likely to be filled [25] , along with weekend scripts, those written in error, or sent to an outside pharmacy [11, 12] . Patients receiving discharge medication counseling tended to initiate treatment more often [15] , as were individuals receiving emergency room prescriptions rather than those from routine clinic appointments [27] . Diabetic patients who smoked [8] , those prescribed antidepressants without a clear mental health diagnosis [29] , and individuals lacking transportation [31] were nearly twice as likely to be poorly adherent. Finally, patients with insurance coverage other than an HMO and those with shorter coverage periods prior to the initial fill had worse adherence [8] .
Although a statistical meta-analysis falls outside the intended scope of this study, some information of observed strength of association on model variables would be informative, rather than simply the number of times risk factors were examined. As such, Table 2 also provides a summary of reported effect sizes as documented by the study authors. Recognizing the large diversity of adherence definitions, study designs, populations, and analytical approaches, significant factors included specific medication or drug class (OR range 1.50-4.87), the number of disease conditions or illness severity (ORs 1.40-2.78), and medication cost or co-payments (ORs 1.20-7.30). In addition, though less frequently examined and demonstrating somewhat inconsistent effects, lower SES had up to a sixfold association with poor adherence (OR ¼ 6.2), along with other influential factors including medication beliefs and patient characteristics such as race/ ethnicity and age.
Discussion
Although initial adherence and associated factors represent a critical issue, relatively little high-quality work has been conducted targeting this very first treatment phase. Our systematic review revealed only 24 articles covering a period of two decades, representing six different countries and diverse populations. Many studies were of variable methodological quality, documented a range of cohort sizes, and often contained an insufficient description or choice of adherence measures. While a detailed assessment of the methodology and statistical analysis of these articles was not the primary objective, we endeavored to restrict inclusion to articles focused on initial adherence as defined by the study authors. We observed significant overlap with "early" adherence, which in some cases extended to nearly 1 year. Many ineligible articles implied that the goal was "primary or initial" adherence, and used other key words such as nonredemption, discontinuation, or abandonment, which caused additional confusion. Thus, analysis of initial medication adherence and comparisons between studies can be misleading without careful consideration of the definition posed. The fact that similar terminology was used for strikingly different methodological approaches is telling, and suggests that much foundational work is required before a solid working definition of initial adherence is formalized.
Summarizing findings from our central aim, numerous behavioral, psychosocial, and other risk factors were associated with initial nonadherence. These included specific medication type, patient characteristics, comorbidities or illness severity, drug costs, medication beliefs and provider relationships, and a variety of other significant factors. While some articles focused on a single issue, for example, drug class [21] or pharmacy copayments [17] , most studies covered several factors and their contribution to adherence. Not surprisingly, many of the same issues are frequently documented in connection with general adherence, such as common drug classes [32, 33] , differential adherence in younger or minority patents [34] [35] [36] , the role of health beliefs [37, 38] , or the detrimental effect of medication cost [39, 40] . Realizing that the mere prevalence of variables examined does not equate to strength of influence, we did find that certain factors had a much greater effect on poor adherence, including medication type, health status or comorbidities, and patient demographics. Further work is needed to help quantitate the relative role of numerous variables on initial medication behavior.
Yet practically speaking, some factors might assume even greater influence over adherence and later outcomes at the beginning of treatment. For example, although direct personal exposure to first prescriptions cannot perfectly inform future adverse reactions or potential treatment response, patients provided sufficient educational information about their medication (benefits, side effects, instructions) during the clinical encounter are more likely to experience better adherence [41] [42] [43] . Similarly, addressing beliefs about medication efficacy before pharmacotherapy commences increases first-fill behavior [44] , supporting growing evidence that an existing solid therapeutic alliance can greatly improve adherence [45] [46] [47] . Empirical findings in our review concerning medication cost suggest that economic considerations and potential "sticker shock" effects impact initial adherence behavior [14,16,17,22-26,28,] . Plus, as Shrank et al. [25] pointed out, new users of a specific medication are less likely to fill initial prescriptions, representing a crucial opportunity to provide additional information or address concerns. Although many interventions successfully target adherence during all phases of treatment, these are often not cost-effective [48] ; however, some relatively simple efforts such as a pharmacy-based telephone call to confirm prescription receipt only those associated with nonadherence (many drugs also had strong positive, beneficial relationships). † While most studies found about a twofold higher risk of nonadherence in younger patients, one exception was initial antidepressant fills, where van Geffen et al. [29] reported an 80% higher risk in patients older than 60 y. ‡ A tremendous range was noted for effect of SES/income, as reported coefficients varied greatly by age group, gender, and other study variables; several of these eight articles reported multiple values with consistent negative association with adherence. Most studies observed a 30% to 50%þ higher risk of nonadherence for patients with lower SES; conversely, Ko et al. [18] and Jackevicius et al. [15] found that lowincome Canadian patients who were entitled to pharmacy assistance were much less likely to not fill initial prescriptions. § Fischer et al. [13] and Shrank et al. [24] found that men had slightly better adherence, while the other three studies documented about a 30% better adherence rate in women. ÃÃ Significant variability was presented in both self-reported and researcher-defined health status or severity of illness, and in study design (survey, qualitative interviews, secondary data analysis). ∥ A variety of medication co-payment and out-of-pocket cost levels were examined, contributing to a wide range of findings for this factor as well. ORs of 2.0 and above were reported for co-payments of $10 or more and over 4.0 for co-payments of $30 or more. ¶ Neither the Menckeberg et al. article [20] nor the Karter et al. [16] article provided a direct comparative value for this factor and nonadherence. The former study provided only a descriptive prevalence of poor initial adherence on side effects per patient report, while Karter et al. [16] presented the association of nonadherence by treatment response expressed through a range of continuous diabetic outcomes. H 1 6 ( 2 0 1 3 ) 8 9 1 -9 0 0 and provide information to the patient can influence initial adherence [49] . Such organizational interventions introduced at the commencement of treatment rather than later can yield substantial benefits. Out-of-pocket costs are difficult to address, yet individuals perceiving that their treatment is more patient-centered do experience lower cost-related adherence problems [50] .
Unlike numerous studies associating poor adherence in general to negative ramifications, only a few of these publications linked initial nonadherence to clinical outcomes. Jackevicius et al. [15] noted higher mortality in patients receiving fewer initial prescriptions, while Ko et al. [18] observed similar findings for thienopyridine fills following coronary events. In the two Shah et al. [22, 23] studies, patients appropriately filling index prescriptions had a threefold reduction in hemoglobin A 1c levels and significantly lower blood pressure readings versus nonadherent individuals. Because the majority of the 24 studies involved analyses of retrospective databases, it is possible that clinical outcomes data were not available.
Although the Nichol quality assessment tool evaluates several key study facets [7] , including terminology and cohort specification, it might not perfectly capture all quality dimensions and study design limitations. Perhaps significantly, only five studies reported model fit or predictive ability concerning initial adherence; with one exception [10] , the authors acknowledged a "poor ability to explain adherence" [8] , modest at best c-statistics [14, 18] , and low r 2 values [28] . Yet these findings are comparable to many studies of cross-sectional or longer term adherence [51, 52] . Furthermore, few studies [9, 10, 12, 20, 30, 31] directly surveyed patients to solicit reasons for prescription failure, instead offering descriptive studies of pharmacy data sets. Administrative records provide essential information to begin recognizing patients at higher risk for initial adherence problems, but a comprehensive examination surrounding behaviors extends past documenting many of the variables available in this limited set of articles. In addition to methodological advancements, the field needs to move beyond simply listing statistically significant factors associated with adherence and rapidly transition toward a deeper understanding of the rationale underlying these findings. Study limitations begin with a relatively small sample of relevant articles, despite thorough efforts to uncover publications addressing initial adherence. The aforementioned methodological issue defining initial adherence signifies not only a potential problem for included articles but also summarizing and translating our findings within a consistent framework. By extension, longitudinal patient medication experiences and associated factors following initial prescriptions were not examined; ongoing work must continue to refine and evaluate study design approaches and influences on adherence over time for chronic conditions. Only publications in English were eligible for this review, and we did not cover discussions surrounding theoretical issues or conceptual frameworks, nor studies presenting qualitative research objectives. Finally, the fact that several additional, potential relevant articles were revealed in our iterative search raises additional questions about the need for more rigid operational definitions of initial adherence, the use of appropriate key words, and how such issues should guide future research inquiries. Nevertheless, this synthesis of currently available information addresses a knowledge gap to stimulate and structure further research efforts.
This systematic review demonstrates that initial adherence is a complex phenomenon regarding definitional aspects and factors affecting its occurrence. In addition to clinical challenges surrounding initial treatment decisions, researchers and policymakers must understand potential inconsistencies in terminology and methodological approaches when evaluating the current state of the literature. Recognizing the strengths of many studies into initial adherence, we must also acknowledge inherent limitations about principle findings, translating existing work to improve patient care, and shaping future investigations. Initial recommendations for our working group would include a deeper inquiry into study methodology, required to truly distinguish initial adherence from a broader definition of early adherence periods and how this affects interpretation of findings. A much more careful review and codification of the term "initial or primary adherence" should be established to allow comparison of findings across studies. Further research should also address additional psychosocial and financial considerations for why patients are nonadherent, interventions targeting medication beliefs, patient-centered treatment approaches and the therapeutic alliance, physician or health system factors, and interactions of issues that represent barriers to appropriate adherence behavior. This should entail a more rigorous methodological review of the strength of association between risk factors and nonadherence, such as a true meta-analysis approach, after more standardized terminology has been established. Finally, studies examining the association between initial adherence and longitudinal patient outcomes are essential in highlighting the importance of this evolving research.
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